Godavari Biorefineries secures European patent for novel anti-cancer drug composition
Godavari Biorefineries Limited has been granted European Patent No. EP4404920 by the European Patent Office for a novel pharmaceutical composition. The patent covers a process combining anti-cancer compounds with a solubilising agent to improve bioavailability for treating breast and prostate cancers. The disclosure was made under SEBI Regulation 30 on August 11, 2026.
*this image is generated using AI for illustrative purposes only.
Godavari Biorefineries has secured a patent grant from the European Patent Office (EPO) for a pharmaceutical composition comprising novel anti-cancer compounds combined with a solubilising agent. The approval, granted on July 15, 2026, strengthens the company's intellectual property portfolio in the oncology sector by protecting a process designed to enhance the solubility and bioavailability of active therapeutic ingredients.
The patent, titled "Pharmaceutical Composition and a Process to Prepare the Same," specifically addresses the challenge of delivering potent anti-cancer agents through oral administration. By incorporating a solubilising agent, the composition aims to improve the therapeutic potential of the drugs, which is critical for treating various forms of cancer, including breast and prostate cancers. This development marks a significant step in the company's research and development efforts to create more effective pharmaceutical solutions for complex oncological conditions.
Patent Specifications
The following table outlines the key details of the patent grant as disclosed in the filing:
| Parameter: | Details |
|---|---|
| Patent Number: | EP4404920 |
| Grant Date: | July 15, 2026 |
| Granting Authority: | European Patent Office |
| Subject: | Pharmaceutical Composition and Process to Prepare the Same |
| Key Innovation: | Combination of anti-cancer compounds with solubilising agent |
| Target Indications: | Breast and Prostate Cancers |
Strategic Significance
The grant provides Godavari Biorefineries with exclusive rights to the patented composition and its preparation process within designated European Contracting States. This intellectual property protection safeguards the company's innovation against infringement and supports potential future commercialization efforts in European markets. The focus on improving bioavailability through solubilisation techniques highlights the company's commitment to advancing formulation science in oncology.
Regulatory Disclosure
Godavari Biorefineries Limited disclosed the patent approval under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made to the National Stock Exchange of India Limited and BSE Limited on August 11, 2026. Manoj Jain, Company Secretary and Compliance Officer, signed the communication confirming the receipt of the Grant Certificate from the EPO.
Historical Stock Returns for Godavari Biorefineries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +11.39% | +2.61% | -1.20% | -7.98% | -3.19% | -22.07% |
What is the projected timeline for initiating clinical trials to validate the bioavailability improvements of this new composition?
How might this European patent influence Godavari Biorefineries' strategy for seeking regulatory approvals in other key markets like the US or Asia?
Are there potential opportunities for licensing this solubilisation technology to larger pharmaceutical companies specializing in oncology?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
